Bafna Pharmaceuticals Limited
BAFNAPH · ISIN: INE878I01022
Bafna Pharmaceuticals Limited is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE878I01022.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
Bafna Pharmaceuticals Limited - growth of ₹100
Growth of ₹100 invested on 2023-10-31, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
+23.06%
3M
+73.82%
6M
+241.04%
1Y
+237.49%
3Y CAGR
+74.34%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Bafna Pharmaceuticals Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
Not available for this stock yet.
Shareholding Pattern
Not available for this stock yet.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-08-06 | BULK | 6,66,000 |
| 2026-08-06 | BULK | 6,66,000 |
Frequently asked questions
What is Bafna Pharmaceuticals Limited's 1-year and 3-year return?
Bafna Pharmaceuticals Limited's 1-year price return is +237.49%. Its 3-year CAGR (annualized return) is +74.34%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Bafna Pharmaceuticals Limited's latest financial performance?
Bafna Pharmaceuticals Limited's trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹143 Cr, with a TTM profit after tax of ₹8 Cr and an EBITDA margin of null%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹3.29.
What is Bafna Pharmaceuticals Limited's quality score?
Bafna Pharmaceuticals Limited has a Punji quality score of 50 out of 100 as of 2026-03-31. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
Has Bafna Pharmaceuticals Limited seen any recent bulk or block deals?
Yes, as of 2026-08-06 - the most recent recorded deal was a BULK on 2026-08-06 for 6,66,000 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
Stock data · Not financial advice · Past performance does not indicate future returns